시장보고서
상품코드
1309726

세계의 혈전 및 지혈 바이오마커 시장 규모, 점유율, 산업 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 소재지별, 유형별, 지역별 전망과 예측(2023-2030년)

Global Thrombosis And Hemostasis Biomarkers Market Size, Share & Industry Trends Analysis Report By Product, By Application, By End-use, By Location, By Type, By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 347 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 혈전 및 지혈 바이오마커(Thrombosis And Hemostasis Biomarkers) 시장 규모는 2030년 74억 달러에 이를 전망이며, 5.6%의 CAGR로 성장하여 상승할 것으로 예측됩니다.

그러나 지혈과 손상 큰 사례 대응에 대해서는 의사를 비롯한 의료 관계자들 사이의 논의가 계속되고 있습니다. 지혈제 단독으로는 과도한 출혈을 일으키는 것과 같은 큰 상해를 입었을 경우에 그다지 도움이 되지 않습니다. 따라서 향후 몇 년간 이러한 요인이 시장 성장을 방해할 수 있습니다.

제품 전망

제품에 따라 시장은 분석 장비와 시약 및 소모품으로 분류됩니다. 시약 및 소모품 부문은 2022년 시장 가장 높은 수익 점유율을 획득했습니다. 진단 툴 큰 요구, 응고, 출혈성 질환 유병률 상승, 최근 제품 주요 요약 등이 이 부문 시장 우위성의 요인입니다. 시약 및 소모품 부문은 크게 증가할 것으로 예측됩니다.

장소 전망

위치는 임상 실험실 검사와 포인트 오브 케어 검사로 분류됩니다. 2022년 시장은 포인트 오브 케어 검사 분야가 큰 수익 점유율을 기록했습니다. POC 검사는 단 몇 분만에 답을 할 수 있기 때문에 건강 관리 직원에게 유용합니다. POCT는 의원이나 ER, 혹은 환자 자택 등, 종래 임상 실험실 이외 장소도 진단 검사를 실시할 수 있도록 하여 시장을 견인하고 있습니다.

유형별 전망

유형별로는 D 이량체, 항트롬빈 III, 플라스미노겐 및 피브리노겐, 가용성 피브린, 셀렉틴, 인자 VIII, PT, APTT 등으로 분류됩니다. 포스트트롬빈(PT) 부문은 2022년 시장에서 가장 큰 수익 점유율을 보였습니다. 이 검사는 혈전을 멈추는 것을 목표로 하는 와파린과 같은 항응고제가 얼마나 효과적인지를 추적할 수 있게 합니다. 또한 간 질환 및 혈액 질환 진단에도 사용됩니다. 혈액 희석제를 사용하지 않는 사람 경우 일반적으로 혈장이 응고되는 데 11-13.5초가 걸립니다.

용도, 전망

용도에 따라 시장은 심부 정맥 혈전증(DVT), 폐 색전증(PE), 파종 혈관 내 응고 증후군(DIC) 등으로 구분됩니다. 폐색전증(PE) 부문은 2022년 시장 큰 수익 점유율을 보였습니다. 폐 혈관에 혈전이 생기면 팔이나 다리 등별 부위에도 혈전이 생겨 폐색전증으로 알려진 상태가 됩니다. 폐 색전증은 심장 마비, 뇌졸중에 이어 3위이며, 심혈관 질환 중 가장 확산된 질환 중 하나입니다. 예를 들어 미국 폐협회는 2023년 1월 현재 매년 약 90만 명 미국인이 PE를 앓고 있다고 추정합니다.

최종 용도, 전망

최종 용도별로는, 시장은 병원 및 진료소, 학술기관 및 연구기관, 진단센터 기타로 분류됩니다. 진단센터 부문은 2022년 시장에서 가장 큰 수익 점유율을 획득했습니다. 병원이 검사 및 평가를 위해 진단센터에 의존하는 경향이 강해지고 있는 것이 점유율의 요인이 되어, 이것이 이 부문의 급속한 확대를 더욱 뒷받침하고 있습니다. 진단 검사 환불 등 다양한 편의 시설을 제공하는 정부 이니셔티브 확대는 업계 성장을 가속할 것으로 예상되는 또 다른 중요 요소입니다.

지역별 전망

지역별로 시장은 북미, 유럽, 아시아태평양, LAMEA로 나뉩니다. 북미 부문은 2022년 시장 가장 큰 수익 점유율을 획득했습니다. 혈전증, 지혈 장애 빈도 상승, 기술 신흥국 시장 개척, 혈전 및 지혈 바이오마커 연구 개발 진행이 이 지역 시장을 추진하는 주된 요인입니다. 예를 들어 미국 질병 예방관리센터에 따르면 미국 정맥혈전색전증(VTE) 연간 사망 예측은 6만-10만 명입니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 주요 요약

  • 소개
    • 주요 요약
      • 시장구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 세계의 혈전 및 지혈 바이오마커 시장 : 제품별

  • 세계의 시약 및 소모품 시장 : 지역별
  • 세계의 분석장치 시장 : 지역별

제4장 세계의 혈전 및 지혈 바이오마커 시장 : 용도별

  • 세계의 심부정맥혈전증(DVT) 시장 : 지역별
  • 세계의 폐색전증(PE) 시장 : 지역별
  • 세계의 파종성 혈관내 응고 증후군(DIC) 및 기타 시장 : 지역별

제5장 세계의 혈전 및 지혈 바이오마커 시장 : 최종 용도별

  • 세계의 진단센터 시장 : 지역별
  • 세계의 병원 및 클리닉 시장 : 지역별
  • 세계의 학술조사기관 및 기타 시장 : 지역별

제6장 세계의 혈전 및 지혈 바이오마커 시장 : 소재지별

  • 세계의 임상 검사 시장 : 지역별
  • 세계의 포인트 오브 케어 검사 시장 : 지역별

제7장 세계의 혈전 및 지혈 바이오마커 시장 : 유형별

  • 세계의 포스트 트롬빈(PT) 시장 : 지역별
  • 세계의 활성화 부분 트롬보플라스틴 시간(APTT) 검사 시장 : 지역별
  • 세계의 D-다이머 시장 : 지역별
  • 세계의 안티트롬빈 III 시장 : 지역별
  • 세계의 플라스미노겐 및 피브리노겐 시장 : 지역별
  • 세계의 가용성 피브린 시장 : 지역별
  • 세계의 셀렉틴 시장 : 지역별
  • 세계의 제VIII인자 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제8장 세계의 혈전 및 지혈 바이오마커 시장 : 지역별

  • 북미
    • 북미 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카, 중동, 아프리카
    • 라틴아메리카, 중동, 아프리카 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 라틴아메리카, 중동, 아프리카

제9장 기업 프로필

  • Thermo Fisher Scientific, Inc
  • F Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG(Siemens AG)
  • Abbott Laboratories
  • BioMerieux SA
  • Horiba Ltd
  • QuidelOrtho Corporation
  • Werfen, SA
  • Diazyme Laboratories, Inc(General Atomics)
  • BioMedica Diagnostics Inc(Scotia Investments Family of Companies)
NJH 23.08.24

The Global Thrombosis And Hemostasis Biomarkers Market size is expected to reach $7.4 billion by 2030, rising at a market growth of 5.6% CAGR during the forecast period.

Clinical Laboratory Test are growing for evaluating the extremity of the illness and inform therapy choices. Moreover, the growing aging population emerges the need for frequent lab tests especially in emerging nations. Therefore, clinical laboratory tests are expected to capture more than 65% share of the market by 2029. For example, by 2050, it is expected that the world population will reach almost 1.5 billion, up by more than triple. Additionally, it is anticipated that the proportion of senior individuals worldwide will rise to 16.0% in this period. By the middle of the 21st century, one in six individuals will be 65 or older. The "population aging phenomenon" refers to the increasing prevalence and proportion of older people in the world's population. In addition, 703 million individuals worldwide in 2019 were 65 or older. Some of the factors impacting the market are increased occurrence of chronic disorders, rising demand for personalized medications, and limitations regarding the use of hemostasis biomarkers.

Chronic diseases or noncommunicable diseases (NCDs) are becoming more commonplace on an international level. Hemostasis and thrombosis tests help to regulate the occurrence of a variety of health conditions, illnesses, injuries, or afflictions of chronic diseases. Apart from helping patients recover quickly and achieve the greatest results, it supports further medical interventions, like surgical procedures. The rapidly rising need for personalized medicine to treat various illnesses and disorders in accordance with a specific patient's needs is one of the key drivers fueling the demand. This element is promoting the market. The COVID-19 pandemic favorably impacted the market. According to the National Library of Medicine findings in September 2020, thrombotic problems were quite common in COVID-19 patients. These complications were a contributing factor in the high death and morbidity rates. The pandemic raised awareness, generating major new opportunities for market competition.

However, on the question of hemostasis and how to manage cases with significant damage, discussions among doctors and other medical professionals are still ongoing. A hemostatic agent by itself would not be very helpful in the event that a person suffers a significant injury that causes excessive blood loss. Hence, in the coming years, these factors may impede the growth of the market.

Product Outlook

Based on product, the market is characterized into analyzers and reagents & consumables. The reagents and consumables segment garnered the highest revenue share in the market in 2022. The substantial need for diagnostic tools, the rising prevalence of coagulation and bleeding disorders, and recent product introductions are all factors that contributed to the segment's market dominance. Throughout the projected period, the reagents and consumables segment are anticipated to increase significantly.

Location Outlook

On the basis of location, the market is classified into clinical laboratory tests and point-of-care tests. The point-of-care tests segment recorded a significant revenue share in the market in 2022. Since POC tests can deliver answers in just a few minutes, they are convenient for healthcare practitioners. The market is driven by POCT, which enables diagnostic tests to be conducted outside of traditional clinical laboratory environments, such as doctor's offices, ERs, or even patients' homes.

Type Outlook

By type, the market is divided into D-dimer, anti-thrombin III, plasminogen & fibrinogen, soluble fibrin, selectins, factor VIII, PT, APTT, and others. The post-thrombin (PT) segment witnessed the maximum revenue share in the market in 2022. The test makes it possible to keep track of how well anticoagulant drugs, such as warfarin, which are intended to stop blood clots, are working. Additionally, it is used to diagnose liver illnesses and blood disorders. For people who are not using blood thinners, it normally takes blood plasma 11 to 13.5 seconds to clot.

Application Outlook

Based on application, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. The pulmonary embolism (PE) segment witnessed a significant revenue share in the market in 2022. Blood clots in the lungs' blood vessels can also form in other body regions like the arms or legs and lead to the condition known as pulmonary embolism. PE is one of the most prevalent forms of cardiovascular disease, ranking third after heart attack and stroke. For instance, the American Lung Association estimates that almost 900,00 Americans are affected with PE each year as of January 2023.

End Use Outlook

On the basis of end-use, the market is categorized into hospitals & clinics, academic & research institutes, diagnostic centers, and others. The diagnostic centers segment garnered the largest revenue share in the market in 2022. The increase in hospitals' reliance on diagnostic centers for testing and assessment is likely to be responsible for the share, which further fuels the segment's rapid expansion. The expansion of government initiatives to offer various amenities, such as reimbursement for diagnostic testing, is another significant element anticipated to fuel industry growth.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment acquired the maximum revenue share in the market in 2022. The rising frequency of thrombosis and hemostasis disorders, technological developments, and ongoing R&D in thrombosis and hemostasis biomarkers are the main factors propelling the market in this region. As an illustration, according to the Centers for Disease Control and Prevention, the predicted yearly mortality of venous thromboembolism (VTE) in this the US ranges from 60,000 to 100,000.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMerieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).

Scope of the Study

Market Segments covered in the Report:

By Product

  • Reagents & Consumables
  • Analyzers

By Application

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Disseminated Intravascular Coagulation (DIC) & Others

By End-Use

  • Diagnostic Centers
  • Hospitals & Clinics
  • Academic & Research Institutes and Others

By Location

  • Clinical Laboratory Tests
  • Point-of-Care Tests

By Type

  • Post-Thrombin (PT)
  • Activated Partial Thromboplastin Time (APTT) Test
  • D-Dimer
  • Anti-Thrombin III
  • Plasminogen & Fibrinogen
  • Soluble Fibrin
  • Selectins
  • Factor VIII
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG (Siemens AG)
  • Abbott Laboratories
  • BioMerieux S.A.
  • Horiba Ltd.
  • QuidelOrtho Corporation
  • Werfen, S.A.
  • Diazyme Laboratories, Inc. (General Atomics)
  • BioMedica Diagnostics Inc. (Scotia Investments Family of Companies)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Thrombosis And Hemostasis Biomarkers Market, by Product
    • 1.4.2 Global Thrombosis And Hemostasis Biomarkers Market, by Application
    • 1.4.3 Global Thrombosis And Hemostasis Biomarkers Market, by End-Use
    • 1.4.4 Global Thrombosis And Hemostasis Biomarkers Market, by Location
    • 1.4.5 Global Thrombosis And Hemostasis Biomarkers Market, by Type
    • 1.4.6 Global Thrombosis And Hemostasis Biomarkers Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Thrombosis And Hemostasis Biomarkers Market by Product

  • 3.1 Global Reagents & Consumables Market by Region
  • 3.2 Global Analyzers Market by Region

Chapter 4. Global Thrombosis And Hemostasis Biomarkers Market by Application

  • 4.1 Global Deep Vein Thrombosis (DVT) Market by Region
  • 4.2 Global Pulmonary Embolism (PE) Market by Region
  • 4.3 Global Disseminated Intravascular Coagulation (DIC) & Others Market by Region

Chapter 5. Global Thrombosis And Hemostasis Biomarkers Market by End-use

  • 5.1 Global Diagnostic Centers Market by Region
  • 5.2 Global Hospitals & Clinics Market by Region
  • 5.3 Global Academic & Research Institutes and Others Market by Region

Chapter 6. Global Thrombosis And Hemostasis Biomarkers Market by Location

  • 6.1 Global Clinical Laboratory Tests Market by Region
  • 6.2 Global Point-of-Care Tests Market by Region

Chapter 7. Global Thrombosis And Hemostasis Biomarkers Market by Type

  • 7.1 Global Post-Thrombin (PT) Market by Region
  • 7.2 Global Activated Partial Thromboplastin Time (APTT) Test Market by Region
  • 7.3 Global D-Dimer Market by Region
  • 7.4 Global Anti-Thrombin III Market by Region
  • 7.5 Global Plasminogen & Fibrinogen Market by Region
  • 7.6 Global Soluble Fibrin Market by Region
  • 7.7 Global Selectins Market by Region
  • 7.8 Global Factor VIII Market by Region
  • 7.9 Global Others Market by Region

Chapter 8. Global Thrombosis And Hemostasis Biomarkers Market by Region

  • 8.1 North America Thrombosis And Hemostasis Biomarkers Market
    • 8.1.1 North America Thrombosis And Hemostasis Biomarkers Market by Product
      • 8.1.1.1 North America Reagents & Consumables Market by Country
      • 8.1.1.2 North America Analyzers Market by Country
    • 8.1.2 North America Thrombosis And Hemostasis Biomarkers Market by Application
      • 8.1.2.1 North America Deep Vein Thrombosis (DVT) Market by Country
      • 8.1.2.2 North America Pulmonary Embolism (PE) Market by Country
      • 8.1.2.3 North America Disseminated Intravascular Coagulation (DIC) & Others Market by Country
    • 8.1.3 North America Thrombosis And Hemostasis Biomarkers Market by End-use
      • 8.1.3.1 North America Diagnostic Centers Market by Country
      • 8.1.3.2 North America Hospitals & Clinics Market by Country
      • 8.1.3.3 North America Academic & Research Institutes and Others Market by Country
    • 8.1.4 North America Thrombosis And Hemostasis Biomarkers Market by Location
      • 8.1.4.1 North America Clinical Laboratory Tests Market by Country
      • 8.1.4.2 North America Point-of-Care Tests Market by Country
    • 8.1.5 North America Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.1.5.1 North America Post-Thrombin (PT) Market by Country
      • 8.1.5.2 North America Activated Partial Thromboplastin Time (APTT) Test Market by Country
      • 8.1.5.3 North America D-Dimer Market by Country
      • 8.1.5.4 North America Anti-Thrombin III Market by Country
      • 8.1.5.5 North America Plasminogen & Fibrinogen Market by Country
      • 8.1.5.6 North America Soluble Fibrin Market by Country
      • 8.1.5.7 North America Selectins Market by Country
      • 8.1.5.8 North America Factor VIII Market by Country
      • 8.1.5.9 North America Others Market by Country
    • 8.1.6 North America Thrombosis And Hemostasis Biomarkers Market by Country
      • 8.1.6.1 US Thrombosis And Hemostasis Biomarkers Market
        • 8.1.6.1.1 US Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.1.6.1.2 US Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.1.6.1.3 US Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.1.6.1.4 US Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.1.6.1.5 US Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.1.6.2 Canada Thrombosis And Hemostasis Biomarkers Market
        • 8.1.6.2.1 Canada Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.1.6.2.2 Canada Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.1.6.2.3 Canada Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.1.6.2.4 Canada Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.1.6.2.5 Canada Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.1.6.3 Mexico Thrombosis And Hemostasis Biomarkers Market
        • 8.1.6.3.1 Mexico Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.1.6.3.2 Mexico Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.1.6.3.3 Mexico Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.1.6.3.4 Mexico Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.1.6.3.5 Mexico Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.1.6.4 Rest of North America Thrombosis And Hemostasis Biomarkers Market
        • 8.1.6.4.1 Rest of North America Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.1.6.4.2 Rest of North America Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.1.6.4.3 Rest of North America Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.1.6.4.4 Rest of North America Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.1.6.4.5 Rest of North America Thrombosis And Hemostasis Biomarkers Market by Type
  • 8.2 Europe Thrombosis And Hemostasis Biomarkers Market
    • 8.2.1 Europe Thrombosis And Hemostasis Biomarkers Market by Product
      • 8.2.1.1 Europe Reagents & Consumables Market by Country
      • 8.2.1.2 Europe Analyzers Market by Country
    • 8.2.2 Europe Thrombosis And Hemostasis Biomarkers Market by Application
      • 8.2.2.1 Europe Deep Vein Thrombosis (DVT) Market by Country
      • 8.2.2.2 Europe Pulmonary Embolism (PE) Market by Country
      • 8.2.2.3 Europe Disseminated Intravascular Coagulation (DIC) & Others Market by Country
    • 8.2.3 Europe Thrombosis And Hemostasis Biomarkers Market by End-use
      • 8.2.3.1 Europe Diagnostic Centers Market by Country
      • 8.2.3.2 Europe Hospitals & Clinics Market by Country
      • 8.2.3.3 Europe Academic & Research Institutes and Others Market by Country
    • 8.2.4 Europe Thrombosis And Hemostasis Biomarkers Market by Location
      • 8.2.4.1 Europe Clinical Laboratory Tests Market by Country
      • 8.2.4.2 Europe Point-of-Care Tests Market by Country
    • 8.2.5 Europe Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.5.1 Europe Post-Thrombin (PT) Market by Country
      • 8.2.5.2 Europe Activated Partial Thromboplastin Time (APTT) Test Market by Country
      • 8.2.5.3 Europe D-Dimer Market by Country
      • 8.2.5.4 Europe Anti-Thrombin III Market by Country
      • 8.2.5.5 Europe Plasminogen & Fibrinogen Market by Country
      • 8.2.5.6 Europe Soluble Fibrin Market by Country
      • 8.2.5.7 Europe Selectins Market by Country
      • 8.2.5.8 Europe Factor VIII Market by Country
      • 8.2.5.9 Europe Others Market by Country
    • 8.2.6 Europe Thrombosis And Hemostasis Biomarkers Market by Country
      • 8.2.6.1 Germany Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.1.1 Germany Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.1.2 Germany Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.1.3 Germany Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.1.4 Germany Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.1.5 Germany Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.2 UK Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.2.1 UK Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.2.2 UK Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.2.3 UK Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.2.4 UK Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.2.5 UK Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.3 France Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.3.1 France Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.3.2 France Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.3.3 France Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.3.4 France Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.3.5 France Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.4 Russia Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.4.1 Russia Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.4.2 Russia Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.4.3 Russia Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.4.4 Russia Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.4.5 Russia Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.5 Spain Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.5.1 Spain Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.5.2 Spain Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.5.3 Spain Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.5.4 Spain Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.5.5 Spain Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.6 Italy Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.6.1 Italy Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.6.2 Italy Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.6.3 Italy Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.6.4 Italy Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.6.5 Italy Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.2.6.7 Rest of Europe Thrombosis And Hemostasis Biomarkers Market
        • 8.2.6.7.1 Rest of Europe Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.2.6.7.2 Rest of Europe Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.2.6.7.3 Rest of Europe Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.2.6.7.4 Rest of Europe Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.2.6.7.5 Rest of Europe Thrombosis And Hemostasis Biomarkers Market by Type
  • 8.3 Asia Pacific Thrombosis And Hemostasis Biomarkers Market
    • 8.3.1 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Product
      • 8.3.1.1 Asia Pacific Reagents & Consumables Market by Country
      • 8.3.1.2 Asia Pacific Analyzers Market by Country
    • 8.3.2 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Application
      • 8.3.2.1 Asia Pacific Deep Vein Thrombosis (DVT) Market by Country
      • 8.3.2.2 Asia Pacific Pulmonary Embolism (PE) Market by Country
      • 8.3.2.3 Asia Pacific Disseminated Intravascular Coagulation (DIC) & Others Market by Country
    • 8.3.3 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by End-use
      • 8.3.3.1 Asia Pacific Diagnostic Centers Market by Country
      • 8.3.3.2 Asia Pacific Hospitals & Clinics Market by Country
      • 8.3.3.3 Asia Pacific Academic & Research Institutes and Others Market by Country
    • 8.3.4 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Location
      • 8.3.4.1 Asia Pacific Clinical Laboratory Tests Market by Country
      • 8.3.4.2 Asia Pacific Point-of-Care Tests Market by Country
    • 8.3.5 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.5.1 Asia Pacific Post-Thrombin (PT) Market by Country
      • 8.3.5.2 Asia Pacific Activated Partial Thromboplastin Time (APTT) Test Market by Country
      • 8.3.5.3 Asia Pacific D-Dimer Market by Country
      • 8.3.5.4 Asia Pacific Anti-Thrombin III Market by Country
      • 8.3.5.5 Asia Pacific Plasminogen & Fibrinogen Market by Country
      • 8.3.5.6 Asia Pacific Soluble Fibrin Market by Country
      • 8.3.5.7 Asia Pacific Selectins Market by Country
      • 8.3.5.8 Asia Pacific Factor VIII Market by Country
      • 8.3.5.9 Asia Pacific Others Market by Country
    • 8.3.6 Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Country
      • 8.3.6.1 China Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.1.1 China Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.1.2 China Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.1.3 China Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.1.4 China Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.1.5 China Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.2 Japan Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.2.1 Japan Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.2.2 Japan Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.2.3 Japan Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.2.4 Japan Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.2.5 Japan Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.3 India Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.3.1 India Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.3.2 India Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.3.3 India Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.3.4 India Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.3.5 India Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.4 South Korea Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.4.1 South Korea Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.4.2 South Korea Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.4.3 South Korea Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.4.4 South Korea Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.4.5 South Korea Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.5 Singapore Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.5.1 Singapore Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.5.2 Singapore Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.5.3 Singapore Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.5.4 Singapore Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.5.5 Singapore Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.6 Malaysia Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.6.1 Malaysia Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.6.2 Malaysia Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.6.3 Malaysia Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.6.4 Malaysia Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.6.5 Malaysia Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.3.6.7 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market
        • 8.3.6.7.1 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.3.6.7.2 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.3.6.7.3 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.3.6.7.4 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.3.6.7.5 Rest of Asia Pacific Thrombosis And Hemostasis Biomarkers Market by Type
  • 8.4 LAMEA Thrombosis And Hemostasis Biomarkers Market
    • 8.4.1 LAMEA Thrombosis And Hemostasis Biomarkers Market by Product
      • 8.4.1.1 LAMEA Reagents & Consumables Market by Country
      • 8.4.1.2 LAMEA Analyzers Market by Country
    • 8.4.2 LAMEA Thrombosis And Hemostasis Biomarkers Market by Application
      • 8.4.2.1 LAMEA Deep Vein Thrombosis (DVT) Market by Country
      • 8.4.2.2 LAMEA Pulmonary Embolism (PE) Market by Country
      • 8.4.2.3 LAMEA Disseminated Intravascular Coagulation (DIC) & Others Market by Country
    • 8.4.3 LAMEA Thrombosis And Hemostasis Biomarkers Market by End-use
      • 8.4.3.1 LAMEA Diagnostic Centers Market by Country
      • 8.4.3.2 LAMEA Hospitals & Clinics Market by Country
      • 8.4.3.3 LAMEA Academic & Research Institutes and Others Market by Country
    • 8.4.4 LAMEA Thrombosis And Hemostasis Biomarkers Market by Location
      • 8.4.4.1 LAMEA Clinical Laboratory Tests Market by Country
      • 8.4.4.2 LAMEA Point-of-Care Tests Market by Country
    • 8.4.5 LAMEA Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.5.1 LAMEA Post-Thrombin (PT) Market by Country
      • 8.4.5.2 LAMEA Activated Partial Thromboplastin Time (APTT) Test Market by Country
      • 8.4.5.3 LAMEA D-Dimer Market by Country
      • 8.4.5.4 LAMEA Anti-Thrombin III Market by Country
      • 8.4.5.5 LAMEA Plasminogen & Fibrinogen Market by Country
      • 8.4.5.6 LAMEA Soluble Fibrin Market by Country
      • 8.4.5.7 LAMEA Selectins Market by Country
      • 8.4.5.8 LAMEA Factor VIII Market by Country
      • 8.4.5.9 LAMEA Others Market by Country
    • 8.4.6 LAMEA Thrombosis And Hemostasis Biomarkers Market by Country
      • 8.4.6.1 Brazil Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.1.1 Brazil Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.1.2 Brazil Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.1.3 Brazil Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.1.4 Brazil Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.1.5 Brazil Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.2 Argentina Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.2.1 Argentina Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.2.2 Argentina Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.2.3 Argentina Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.2.4 Argentina Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.2.5 Argentina Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.3 UAE Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.3.1 UAE Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.3.2 UAE Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.3.3 UAE Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.3.4 UAE Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.3.5 UAE Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.4 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.4.1 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.4.2 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.4.3 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.4.4 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.4.5 Saudi Arabia Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.5 South Africa Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.5.1 South Africa Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.5.2 South Africa Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.5.3 South Africa Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.5.4 South Africa Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.5.5 South Africa Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.6 Nigeria Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.6.1 Nigeria Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.6.2 Nigeria Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.6.3 Nigeria Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.6.4 Nigeria Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.6.5 Nigeria Thrombosis And Hemostasis Biomarkers Market by Type
      • 8.4.6.7 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market
        • 8.4.6.7.1 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market by Product
        • 8.4.6.7.2 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market by Application
        • 8.4.6.7.3 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market by End-use
        • 8.4.6.7.4 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market by Location
        • 8.4.6.7.5 Rest of LAMEA Thrombosis And Hemostasis Biomarkers Market by Type

Chapter 9. Company Profiles

  • 9.1 Thermo Fisher Scientific, Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Financial Analysis
    • 9.1.3 Segmental and Regional Analysis
    • 9.1.4 Research & Development Expenses
    • 9.1.5 SWOT Analysis
  • 9.2 F. Hoffmann-La Roche Ltd.
    • 9.2.1 Company Overview
    • 9.2.2 Financial Analysis
    • 9.2.3 Segmental and Regional Analysis
    • 9.2.4 Research & Development Expense
  • 9.3 Siemens Healthineers AG (Siemens AG)
    • 9.3.1 Company Overview
    • 9.3.2 Financial Analysis
    • 9.3.3 Segmental and Regional Analysis
    • 9.3.4 Research & Development Expense
    • 9.3.5 Recent strategies and developments:
      • 9.3.5.1 Product Launches and Product Expansions:
    • 9.3.6 SWOT Analysis
  • 9.4 Abbott Laboratories
    • 9.4.1 Company Overview
    • 9.4.2 Financial Analysis
    • 9.4.3 Segmental and Regional Analysis
    • 9.4.4 Research & Development Expense
    • 9.4.5 SWOT Analysis
  • 9.5 BioMerieux S.A.
    • 9.5.1 Company Overview
    • 9.5.2 Financial Analysis
    • 9.5.3 Segmental and Regional Analysis
    • 9.5.4 Research & Development Expenses
  • 9.6 Horiba Ltd.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Analysis
    • 9.6.3 Regional & Segmental Analysis
    • 9.6.4 Research & Development Expenses
    • 9.6.5 Recent strategies and developments:
      • 9.6.5.1 Product Launches and Product Expansions:
  • 9.7 QuidelOrtho Corporation
    • 9.7.1 Company Overview
    • 9.7.2 Financial Analysis
    • 9.7.3 Regional Analysis
    • 9.7.4 Research & Development Expense
  • 9.8 Werfen, S.A.
    • 9.8.1 Company Overview
  • 9.9 Diazyme Laboratories, Inc. (General Atomics)
    • 9.9.1 Company Overview
  • 9.10. BioMedica Diagnostics Inc. (Scotia Investments Family of Companies)
    • 9.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제